Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine

Expert Review of Vaccines

Volumn 1, Issue 3, 2002, Pages 293-301

  Das, Atze T ^a   Zhou, Xue ^a   Vink, Monique ^a   Klaver, Bep ^a   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

AIDS; Doxycycline; HIV; Tet system; Vaccine

Indexed keywords

DOXYCYCLINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

DNA PACKAGING; DNA VECTOR; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DOXYCYCLINE; GENE THERAPY; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; SAIDS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 0037992815     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.3.293     Document Type: Review

References (46)

1. Graham BS. Clinical trials of HIV vaccines. Ann. Rev. Med. 53, 207-221 (2002).
2. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Ann. Rev. Immunol. 20, 73-99 (2002).
3. Smith SM. HIV Vaccine Development in the Nonhuman Primate Model of AIDS. J. Biomed. Sci. 9, 100-111 (2002). Reviews the SIV/AIDS vaccine studies in monkeys.
4. Sutter G, Haas J. Novel vaccine delivery systems: solutions to HIV vaccine dilemmas? AIDS 15(Suppl. 5), S139-S145 (2001). Overview of the HIV/AIDS vaccine
5. Schultz AM, Bradac JA. The HIV vaccine pipeline, from preclinical co Phase III. AIDS 15(Suppl. 5), S147-S158 (2001).
6. Schnell MJ. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol. Lett. 200, 123-129 (2001).
7. Mooij P, Heeney JL. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20, 304-321 (2001).
8. Hanke T. Prospect of a prophylactic vaccine for HIV. Br. Med. Bull. 58, 205-218 (2001).
9. Peters BS. The basis for HIV immunotherapeutic vaccines. Vaccine 20, 688-705 (2001).
10. Robinson HL. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2, 239-250 (2002).
11. Mascola JR, Nabel GJ. Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol. 13, 489-495 (2001).
12. Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 19, 2210-2215 (2001).
13. Steffens CM, Hope TJ. Recent advances in the understanding of HIV accessory protein function. AIDS 15(Suppl. 5), S21-S26 (2001).
14. Berkhout B. Multiple biological roles associated with the repeat (R) region of the HIV-1 RNA genome. Adv. Pharmacol. 48, 29-73 (2000).
15. Guan Y, Whitney JB, Liang C, Wainberg MA. Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences. J. Virol. 75, 2776-2785 (2001).
16. Kestler HW III, Ringler DJ, Mori K, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662 (1991).
17. Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of SIVmac mutants with deletions in 'nonessential' genes. AIDS Res. Hum. Retroviruses 10, 607-616 (1994).
18. Guan Y, Whitney JB, Detorio M, Wainberg MA. Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. J. Virol. 75, 4056-4067 (2001).
19. Johnson RP. Live attenuated AIDS vaccines: hazards and hopes. Nat. Med. 5, 154-155 (1999).
20. Desrosiers RC. Prospects for live attenuated HIV. Nat. Med. 4, 982 (1998).
21. Mills J, Desrosiers R, Rud E, Almond N. Live attenuated HIV vaccines: proposal for further research and development. AIDS Res. Hum. Retroviruses 16, 1453-1461 (2000).
22. Baba TW, Jeong YS, Penninck D et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
23. Baba TW, Liska V, Khimani AH et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5, 194-203 (1999).
24. Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi species of HIV-1 from blood transfusion donor and recipients. Science 270, 988-991 (1995).
25. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immuodeficiency virus. J. Virol. 70, 3724-3733 (1996).
26. Lohman BL, McChesney MB, Miller CJ et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68, 7021-7029 (1994).
27. Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of HIV-1 mutants with deletions in 'nonessential' genes. AIDS Res. Hum. Retroviruses 10, 343-350 (1994).
28. Desrosiers RC. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res. Hum. Retroviruses 8, 411-421 (1992).
29. Berkhout B, Verhoef K, van Wamel JLB, Back B. Genetic instability of live-attenuated HIV-1 vaccine strains. J. Virol. 73, 1138-1145 (1999).
30. Berkhout B, Silverman RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59, 273-282 (1989).
31. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B. Strict control of HIV-1 replication by a genetic switch: Tet for Tat. J. Virol. 75, 979-987 (2001). Construction of the HIV-rtTA vaccine candidate.
32. Urlinger S, Baron U, Thellmann M et al. Exploring the sequence space for tetracycline dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl Acad. Sci. USA 97, 7963-7968 (2000).
33. Marzio G, Verhoef K, Vink M, Berkhout B. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl Acad. Sci. USA 98, 6342-6347 (2001). Optimization of HIV-rtTA by spontaneous virus evolution.
34. Marzio G, Vink M, Verhoef K, de Ronde A, Berkhout B. Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription. J. Virol. 76, 3084-3088 (2002).
35. Kent SJ, Dale CJ, Preiss S et al. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation. J. Virol. 75, 11930-11934 (2001).
36. Berkhout B, Marzio G, Verhoef K. Control over HIV-1 replication by an antibiotic; a novel vaccination strategy with a drug-dependent virus. Virus Res. 82, 103-108 (2002).
37. Joshi N, Miller DQ. Doxycydine revisited. Arch. Intern. Med. 157, 1421-1428 (1997).
38. Kelly DJ, Chulay JD, Mikesell P, Friedlander AM. Serum concentrations of penicillin, doxycycline and ciprofloxacin during prolonged therapy in rhesus monkeys. J. Infect. Dis. 166, 1184-1187 (1992).
39. Sauer B. Site-specific recombination: developments and applications. Curr. Opin. Biotechnol. 5, 521-527 (1994).
40. Smith SM, Markham RB, Jeang K-T. Conditional reduction of human immunodeficiency virus Type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Proc. Natl Acad. Sci. USA 93, 7955-7960 (1996).
41. Chakrabarti BK, Maitra RK, Ma XZ, Kestler HW. A candidate live inactivatable attenuated vaccine for AIDS. Proc. Natl Acad. Sci. USA 93, 9810-9815 (1996).
42. Baron U, Bujard H. Tet repressor-base system for regulated gene expression in eukaryotic cells: principles and advances. Meth. Enzymol. 327, 401-421 (2000). Describes ins and outs of the Tet system.
43. Freundlieb S, Baron U, Bonin AL, Gossen M, Bujard H. Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. Meth. Enzymol. 283, 159-173 (1997).
44. Xiao Y, Kuwata T, Miura T, Hayami M, Shida H. Dox-dependent SIVmac with tetracycline-inducible promoter in the U3 promoter region. Virol. 269, 268-275 (2000).
45. Smith SM, Khoroshev M, Marx PA, Orenstein J, Jeang KT. Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine. J. Biol. Chem. 276, 32184-32190 (2001).
46. Hillen W, Berens C. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Ann. Rev. Microbiol. 48, 345-369 (1994).